Association of the p.Phe155del mutation in SERPINC1 with changed antithrombin function and increased risk of venous thromboembolism: clinical and functional observations Authors: Jing Lu, Zuoyu Qin, Yining Lan, Jianlin Zhang, Zhilin Yu, Jialan Liang, Yanyan Tang Published: 2025 ABSTRACT IntroductionAntithrombin (AT) deficiency, often caused by mutations in the SERPINC1 gene, is a well-established risk factor for venous thromboembolism (VTE), which can lead to serious complications such as deep vein thrombosis (DVT), pulmonary embolism (PE), and cerebral venous sinus thrombosis (CVST). Syndecan-4 (SDC4), an endothelial cell membrane protein, enhances AT’s anticoagulant function by facilitating its interaction with the vascular endothelium, thereby supporting hemostatic balance.MethodsOur team enrolled a patient diagnosed with CVST, and subsequent genetic testing identified the SERPINC1 p.Phe155del variant. This study sought to elucidate the interaction between AT mutations and SDC4 in VTE pathogenesis using clinical case analyses, molecular docking, co-immunoprecipitation (Co-IP), and immunofluorescence assays.ResultsThe patient was diagnosed with Type I hereditary AT deficiency, with a five-generation family pedigree constructed. Molecular docking simulations showed the SERPINC1 p.Phe155del variant weakened the protein’s interaction with SDC4. Cell-level co-immunoprecipitation and immunofluorescence results were consistent with molecular docking findings, confirming that the SERPINC1 p.Phe155del mutant binds less strongly to SDC4 than the wild-type.ConclusionThis reduced binding may underlie hereditary AT deficiency and increased venous thrombosis risk. The findings from this research deepen understanding of the connection between hereditary hypercoagulable states and VTE —with CVST as one possible clinical manifestation—offering new insights to inform clinical diagnosis and treatment.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12959-025-00802-z. Introduction VTE is a major clinical concern, defined by the blood clots in the venous system that can lead to serious complications, including DVT, PE, and CVST. CVST is an infrequent but critical neurological disorder. This thrombotic event obstructs cerebral venous outflow, resulting in a range of clinical manifestations such as headache, seizures, and altered consciousness. While CVST and other forms of VTE occur in distinct anatomical locations, they share many common risk factors—including genetic predispositions, lifestyle factors, and medical conditions. Though CVST has a relatively low incidence, estimated at over 10 per 1,000,000 annually, it is associated with substantially higher rates of disability and mortality compared to numerous other thrombotic conditions. The populations most susceptible to CVST include young individuals, women of reproductive age, and patients with a prothrombotic condition [1, 2]. Notably, recent studies have underscored the key role of genetic factors in thrombosis: several inherited coagulation disorders are recognized as important CVST risk factors, including AT deficiency, protein C and protein S deficiencies, and the factor V Leiden mutation [3, 4]. Mutations in the SERPINC1 gene are closely linked to hereditary AT deficiency, a rare autosomal dominant thrombotic disorder. Previous studies have identified diverse SERPINC1 mutations associated with different types of AT deficiency. For example, one study identified a SERPINC1 c.1247dupC mutation linked to protein secretion defects and quantitative AT deficiency; this mutation induces a frameshift in the coding sequence, altering the C-terminus of the antigen and leading to impaired secretion [5]. Separately, another study detected two SERPINC1 point mutations (W221C and M248R) in patients with hereditary AT deficiency, suggesting that these mutations may affect the secretion and production of AT by disrupting the central β-sheet of the protein [6]. Additional research has found that the SERPINC1 p.Lys322 stop variant leads to a severe tendency to form blood clots. This variant affects the secretion of AT by producing truncated proteins, resulting in a lack of AT [7]. Among these mutations, the p.Phe155del variant has been consistently linked to a severe thrombotic phenotype, including life-threatening events like CVST and DVT, across multiple independent families and ethnicities. This confirms that the p.Phe155del mutation is a primary pathogenic driver, not a benign polymorphism. Under physiological conditions, Phe-122 (also referred to as Phe-155) plays a crucial role in forming and stabilizing heparin- AT complexes [8]. Additionally, the transmembrane protein SDC4, as a heparin sulfate proteoglycan (HSPG), plays an important regulatory role in vascular endothelial cells. HSPG has multiple functions in biological processes such as cell signaling, cell adhesion, and blood coagulation. SDC4’s key role in the coagulation process lies in its ability to bind to AT and boost AT’s anticoagulant activity by several orders of magnitude, thereby playing an important role in maintaining blood coagulation balance [9, 10]. Therefore, abnormal binding of SDC4 to AT may lead to an increase in thrombotic tendency and further promote the occurrence of VTE. This study aims to explore the role of the mutant AT-SDC4 interactions in VTE pathogenesis via clinical case analysis and protein function evaluation. Specifically, we will examine the diagnosis and treatment of a 16-year-old male patient with CVST to identify potential genetic factors. Furthermore, the association between hereditary AT mutations and SDC4 will be corroborated using molecular docking, immunoprecipitation, and confocal laser scanning techniques. The findings from this research are expected to deepen the understanding of the relationship between hereditary hypercoagulable states and VTE, offering novel insights for clinical diagnosis and treatment strategies. Methods Participants This study investigated a five-generation pedigree from southern China with a total of 30 individuals. Peripheral blood was collected from 25 surviving individuals in the family using qualified negative pressure vacuum EDTA anticoagulation tubes for whole genome testing. The report of the proband’s blood tests was generated by the Laboratory Department of The First Affiliated Hospital of Guangxi Medical University. Whole-genome high-throughput sequencing This project uses whole-genome high-throughput sequencing technology to sequence the human genome (Guangzhou KingMed Medical Testing Center Co., Ltd.). Genomic DNA is extracted from blood and sequenced using the PCR-free method on the Illumina sequencing platform. The average sequencing depth of the obtained data on the human nuclear genome sequence is ≥ 30X, and the average sequencing depth of the mitochondrial DNA sequencing data is ≥ 800X. Among them, at least 98% of the sequences in the whole genome have a sequencing depth of more than 10X, and at least 90% of the sequences have a sequencing depth of more than 20X. Molecular docking In order to predict the changes in the binding ability of wild-type and mutant AT with SDC4 and heparin, we performed molecular docking analysis. First, the three-dimensional structures of AT (ID: 1E03, which contains heparin, species: Homo sapiens) and SDC4 (ID: 1EJP, species: Homo sapiens) were downloaded from the PDB database. We used the heparin-bound AT structure (PDB: 1E03) as a proxy for the HSPG-engaged conformation of AT at the endothelial surface. This choice provides a consistent conformational baseline to compare wild-type and mutant AT in silico when assessing predicted interaction with SDC4. The three-dimensional structures of the above proteins were pre-processed by removing water molecules and other heteroatoms using AutoDock software [11]. The maximum number of conformations generated by molecular docking was set to 20 models, and the Lamarckian genetic algorithm (LGA) was used for global search. Finally, PyMoL2.3 software (https://www.pymol.org/) was used for detailed analysis, and key residues of wild-type, mutant AT and SDC4 were determined. Cell culture, mutant construction, and plasmid transfection The Human Umbilical Vein Endothelial Cells (HUVECs) were maintained in 10-cm culture dishes with high-glucose Dulbecco’s Modified Eagle Medium (Servicebio, cat#G4003、G4511) supplemented with 10% fetal bovine serum (Gibco, Auckland, New Zealand) and 1% penicillin-streptomycin mix, at 37 °C with 5% CO₂ incubator. Three tagged plasmids were constructed with support from Genechem (Shanghai, China): CMV enhancer-SDC4-MYC-MCS-SV40-puromycin, CMV enhancer-SERPINC1-FLAG-MCS-SV40-puromycin, and CMV enhancer-SERPINC1 p.Phe155del-FLAG-MCS-SV40-puromycin. Plasmid transfection was performed using the Lipo3000 reagent (ThermoFisher, cat#L3000015) according to the manufacturer’s protocol. Co-immunoprecipitation and western blot analysis Total proteins were extracted from HUVECs in 10-cm culture dishes that had been co-transfected with tagged plasmids, using a cell lysis buffer from Co-IP KIT (Bersinbio, Guangzhou, China, cat#Bes3011), which contains protease inhibitors to maintain protein stability during extraction. Myc and Flag tag antibodies (Cell Signaling Technology, cat#14793S and 2276 S) bind to the target protein, forming an antibody-antigen complex. Protein A/G magnetic beads were then added to capture the antibody-antigen complex. Multiple washing steps were performed to remove non-specifically bound components, ensuring that only the target protein and its interacting partners were retained. The protein complexes were subsequently eluted using an elution buffer. The protein sample was mixed with 5× SDS-PAGE loading buffer at a 5:1 ratio (v/v) and then denatured by boiling at 95–100 °C for 5–10 min. The denatured samples were loaded onto an 8% to 10% SDS-PAGE gel at 5 µL per well. Electrophoresis was conducted using rapid electrophoresis buffer (Servicebio, cat#G2081-1 L) at a steady voltage of 225 V for about 30 min until the dye front reached the bottom of the gel. Following electrophoresis, proteins were transferred to a 0.22-µm polyvinylidene fluoride PVDF membrane (pre-activated with methanol) using rapid transfer buffer (Servicebio, cat#G2148-1 L) at a constant current of 400 mA for 40 min. The membrane was then incubated with Protein-Free Quick Blocking Solution (Servicebio, cat#G2052-500ML) for 20 min at room temperature. Subsequently, the membrane was incubated with primary antibody (Cell Signaling Technology, cat#14793S and 2276 S) at 4 °C overnight with gentle shaking. The membrane was washed several times with TBS-T to remove excess primary antibody and reduce background signal. Subsequently, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (ZENBIO, cat# 511103 and cat#511203) for 1 h at room temperature with gentle shaking. Ultrasensitive ECL chemiluminescent solution was applied to the membrane, which can be detected using a chemiluminescent imaging system. Cell immunofluorescence After plasmid transfection, cells were cultured for an additional 24 h. The cells were then fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. To block non-specific binding, cells were incubated with 5% bovine serum albumin for 1 h at room temperature. The cells were subsequently incubated overnight at 4 °C with the primary antibody (Cell Signaling Technology, cat#14793S and 2276 S) specific to the target protein. After each step, the cells were washed 3–5 times with PBS to remove excess reagents. Following the primary antibody incubation, the cells were incubated with a fluorophore-conjugated secondary antibody (Cell Signaling Technology, cat#8890S and 4412 S) for 1 h at room temperature in the dark. Finally, the cells were observed and imaged using a Leica SP8 stimulated emission depletion confocal fluorescence microscope. Statistical analysis To analyze immunofluorescence co-localization, z-stack confocal images were processed using Fiji software (vWindows.x64). The coloc 2 plugin within Fiji was used to calculate Pearson’s correlation coefficient (R value), which quantify the degree of co-localization between target proteins. Three independent biological replicates were analyzed, with multiple cells (typically 15–20) quantified per experiment to ensure statistical robustness. The resulting R values were subjected to appropriate statistical tests using GraphPad Prism software (v9.5). For quantitative Co-IP results, band intensities from Western blot analyses were quantified using Fiji software. First, the integrated density values of the target protein bands were normalized to the corresponding immunoprecipitation control bands to account for variations in immunoprecipitation efficiency. Subsequently, a second normalization was performed against the input samples to adjust for differences in total protein expression. This two-step process yielded the final normalized binding level for each experimental condition. Data are presented as the mean ± standard error of the mean (SEM) from a minimum of three independent biological replicates. Statistical significance between two groups was determined using an unpaired, two-tailed Student’s t-test. A p-value of less than 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism software (v9.5). Results Clinical manifestations The study included 30 members from five generations, with three male family members affected by venous thrombotic events, as shown in Fig. 1. The proband (IV-8), a 16-year-old male, presented with CVST. His father (III-8) had a prior history of DVT, and his grandfather (II-3) died at a young age due to a thrombotic event. This clinical spectrum highlights the general thrombotic risk associated with the SERPINC1 p.Phe155del variant, with CVST representing the proband’s manifestation. IV-8 is the proband, who had headaches for 4 days after strenuous exercise and repeated limb convulsions for 1 day. He was diagnosed with superior sagittal sinus thrombosis after CT and CTV examination in the Department of Neurology (Fig. 2A-B). He was immediately given adequate low-molecular-weight heparin for anticoagulation, but the treatment was ineffective and cerebral edema worsened further (Fig. 2C). DSA showed that the superior sagittal sinus thrombosis was more advanced than before (Fig. 2D). Venous sinus thrombectomy was performed through the femoral vein. After repeatedly extracting several thrombi from the patient’s superior sagittal sinus, a filling defect in the superior sagittal sinus was still seen in the follow-up cerebral angiography (Fig. 2E). Considering the heavy thrombus load, a microcatheter was placed in the thrombus through the femoral vein after venous sinus thrombectomy for slow and continuous pumping of urokinase for thrombolysis. The patient’s blood test results indicate that Activated Partial Thromboplastin Time (APTT) gradually increases. Urokinase treatment was discontinued after 3 days due to the patient’s skin bleeding tendency. After a transitional subcutaneous injection of heparin, oral rivaroxaban anticoagulation therapy was used. The patient’s APTT has decreased compared to previous measurements and is fluctuating within the normal range. During the entire treatment, International Normalized Ratio (INR) was monitored to maintain levels within the normal range (the patient’s anticoagulation treatment and changes in coagulation function are shown in Fig. 3), and the patient recovered well (Fig. 2F-H). The patient had no significant past medical history and was not on any medications. Given the clinical suspicion of thrombophilia, laboratory tests revealed that the proband’s AT was 42.5% (reference range: 75%-125%). Genetic testing revealed a heterozygous mutation in the SERPINC1 gene, specifically the p.Phe155del variant (Fig. 2I-J), which is known to impair the function of AT. As shown in Fig. 1, Ⅲ-6, Ⅲ-10, IV-6, IV-7, IV-11, and IV-12 were female asymptomatic heterozygous mutations in SERPINC1 p.Phe155del, and IV-11 and IV-12 were identical twin girls. Fig. 1Pedigree chart of the affected family (five generations). The proband (IV-8) presented with cerebral venous sinus thrombosis, while his father (III-8) had a history of deep vein thrombosis, and his grandfather (II-3) died from a thrombotic event at a young age. Female carriers (III-6, III-10, IV-6, IV-7, IV-11, IV-12) were heterozygous for the SERPINC1 p.Phe155del variant but remained asymptomatic at the time of study. These findings indicate that the variant is associated with increased general thrombotic risk, with CVST representing one clinical manifestation in this family Pedigree chart of the affected family (five generations). The proband (IV-8) presented with cerebral venous sinus thrombosis, while his father (III-8) had a history of deep vein thrombosis, and his grandfather (II-3) died from a thrombotic event at a young age. Female carriers (III-6, III-10, IV-6, IV-7, IV-11, IV-12) were heterozygous for the SERPINC1 p.Phe155del variant but remained asymptomatic at the time of study. These findings indicate that the variant is associated with increased general thrombotic risk, with CVST representing one clinical manifestation in this family Fig. 2Summary of imaging results throughout the patient’s treatment and the genetic testing results: (A-B) First head CT and CTV scan results before anticoagulant treatment. The red arrow indicates a vascular filling defect in CTV imaging. (C) Head CT follow-up results show no improvement in symptoms after a sufficient dose of low-molecular-weight heparin anticoagulant treatment. (D) Pre-venous sinus thrombectomy head DSA Results. The results suggest that the extent of the vascular filling defect has expanded compared to the pre-treatment range. The red arrows indicate vascular filling defects. (E) Head DSA results after venous sinus thrombectomy. (F-H) Head CT follow-up results of the patient after switching to rivaroxaban anticoagulant therapy. (I) The proband’s genetic testing results include the forward and reverse sequences. Genetic testing revealed a heterozygous mutation in the SERPINC1 gene, specifically the p.Phe155del variant. (J) The genetic sequencing results of the proband’s parents Summary of imaging results throughout the patient’s treatment and the genetic testing results: (A-B) First head CT and CTV scan results before anticoagulant treatment. The red arrow indicates a vascular filling defect in CTV imaging. (C) Head CT follow-up results show no improvement in symptoms after a sufficient dose of low-molecular-weight heparin anticoagulant treatment. (D) Pre-venous sinus thrombectomy head DSA Results. The results suggest that the extent of the vascular filling defect has expanded compared to the pre-treatment range. The red arrows indicate vascular filling defects. (E) Head DSA results after venous sinus thrombectomy. (F-H) Head CT follow-up results of the patient after switching to rivaroxaban anticoagulant therapy. (I) The proband’s genetic testing results include the forward and reverse sequences. Genetic testing revealed a heterozygous mutation in the SERPINC1 gene, specifically the p.Phe155del variant. (J) The genetic sequencing results of the proband’s parents Fig. 3Monitoring of activated partial thromboplastin time (blue) and international normalized ratio (red) under different anticoagulation regimens during the patient’s treatment Monitoring of activated partial thromboplastin time (blue) and international normalized ratio (red) under different anticoagulation regimens during the patient’s treatment Genetic analysis of the SERPINC1 p.Phe155del variant The heterozygous c.462_464delCTT (p.Phe155del) variant was identified in the proband and seven family members through whole-genome sequencing (Fig. 1). This variant was absent in 1,614,192 alleles from healthy controls in the gnomAD database (v4.1.0), with a minor allele frequency (MAF) of 6.195E-7, consistent with its classification as a rare pathogenic variant known to predispose carriers to VTE. In this family, clinical manifestations ranged from CVST in the proband to DVT and other thrombotic events in earlier generations. According to the American College of Medical Genetics and Genomics (ACMG) Variant Rating Guidelines [12], the mutation was classified as Likely Pathogenic, supported by the following evidence: in vitro expression experiments indicated that it results in a loss of function, and the mutation was absent from the normal control population database. Molecular docking results Since SDC4 can bind to AT and enhance its anticoagulant activity, abnormal binding between the two may increase thrombotic tendency and further promote the occurrence of DVT. We performed molecular docking analysis to further explore the effect of the mutant AT on SDC4 binding ability. The results showed that wild-type AT (Fig. 4A) binds to the following sites through hydrogen bonds: Arg 235, Lys 236, Tyr 253, Glu 255, Ile 390, Ala 391, Arg 399 (-Cdocker energy = 664.113 kcal/mol, -Cdocker Interaction energy = 54.0768 kcal/mol). After the p.Phe155del mutate in the SERPINC1 gene (Fig. 4B), the number of binding sites between mutant AT and SDC4 was reduced. (Arg 262, Glu 265, Glu 289), and the binding energy also increased significantly (-Cdocker energy = 705.061 kcal/mol, -Cdocker Interaction energy = 66.3671 kcal/mol), indicating that the interaction between the two was weakened, which may affect the coagulation balance. Fig. 4Verification of the effect of the mutant AT on the binding ability of SDC4 through molecular docking and in vitro cell experiment: (A-B) Molecular docking result. After the SERPINC1 p.Phe155del variant, the number of binding sites between mutant AT and SDC4 decreased, and the binding energy also increased significantly. (C) Representative confocal microscopy images showing the subcellular distribution and co-localization of SDC4 (red) with either wild-type AT (WT-AT, green) or mutant AT (MT-AT, green) in Human Umbilical Vein Endothelial cells. Nuclei were stained with DAPI (blue). Yellow coloration in the merged panels indicates areas of co-localization. Scale bar:10 μm. (D) The co-immunoprecipitation assay revealed a reduction in the interaction between the mutant AT and SDC4. (E) Mutant AT exhibits impaired binding to SDC4. Data are from 3 independent experiments and are presented as Mean ± SEM; *P < 0.05 (by Student’s t-test). The binding affinity of the mutant AT to SDC4 was reduced to 64.35% of the wild-type level. (F) Mutant AT shows impaired co-localization with SDC4 in HUVECs. Data are presented as the mean ± SEM. n = 15–20 per group. *P < 0.05 (by Student’s t-test). The co-localization between SDC4 and mutant AT was significantly reduced compared to the wild-type AT interaction Verification of the effect of the mutant AT on the binding ability of SDC4 through molecular docking and in vitro cell experiment: (A-B) Molecular docking result. After the SERPINC1 p.Phe155del variant, the number of binding sites between mutant AT and SDC4 decreased, and the binding energy also increased significantly. (C) Representative confocal microscopy images showing the subcellular distribution and co-localization of SDC4 (red) with either wild-type AT (WT-AT, green) or mutant AT (MT-AT, green) in Human Umbilical Vein Endothelial cells. Nuclei were stained with DAPI (blue). Yellow coloration in the merged panels indicates areas of co-localization. Scale bar:10 μm. (D) The co-immunoprecipitation assay revealed a reduction in the interaction between the mutant AT and SDC4. (E) Mutant AT exhibits impaired binding to SDC4. Data are from 3 independent experiments and are presented as Mean ± SEM; *P < 0.05 (by Student’s t-test). The binding affinity of the mutant AT to SDC4 was reduced to 64.35% of the wild-type level. (F) Mutant AT shows impaired co-localization with SDC4 in HUVECs. Data are presented as the mean ± SEM. n = 15–20 per group. *P < 0.05 (by Student’s t-test). The co-localization between SDC4 and mutant AT was significantly reduced compared to the wild-type AT interaction In vitro study of transfected HUVECs To investigate the effect of the mutant AT on its binding ability with SDC4, HUVECs were co-transfected with Flag-SERPINC1 or Flag-SERPINC1-Phe155del plasmids and Myc-SDC4 plasmid. Immunofluorescence analysis demonstrated significantly reduced co-localization between SDC4 and mutant AT compared to wild-type (*P < 0.05; n = 15–20; Mean ± SEM; Fig. 4C, F). To further validate the reduced binding of the mutant AT with SDC4, a Co-IP assay was performed. Co-IP assays in HUVECs confirmed significantly reduced binding between mutant AT and SDC4, decreasing to 64.35% of wild-type levels (*P < 0.05; n = 3; Mean ± SEM; Fig. 4D-E). The above cell experiments were conducted in three independent trials. Together, the results from both immunofluorescence and Co-IP assays consistently confirm that the mutant AT leads to a reduced binding capacity with SDC4 compared to the wild-type AT. Discussion Clinical analysis Type I and Type II AT deficiencies are two distinct mechanisms that lead to a reduced anticoagulant effect. Type I deficiency is characterized by a quantitative reduction in the synthesis and/or secretion of AT, resulting in lower circulating levels of AT. In contrast, Type II deficiency involves qualitative mutations that affect AT function without decreasing its circulating concentration. The p.Phe155del variant in SERPINC1 is a pathogenic variant that leads to AT deficiency and is associated with increased thrombotic risk [13]. We were constrained by the limitations of our local medical testing infrastructure, which does not include the assay for AT antigen levels. Despite not conducting comprehensive AT assays, the proband’s significantly low AT activity (42.5%, normal range 75–125%) indicates a quantitative deficiency. This is supported by the discovery of the SERPINC1 p.Phe155del variant, known to cause Type I AT deficiency [13–17]. The SERPINC1 p.Phe155del mutation was inherited from the proband’s father, and the heterozygous mutation was found in other family members, including aunts and cousins. The clinical phenotypes observed, including DVT, PE, and CSVT, are consistent with the thrombosis risk associated with AT deficiency. Notably, the proband’s thrombotic event was triggered by severe dehydration due to strenuous exercise, which highlights the importance of managing acquired risk factors such as dehydration, surgery, and trauma in patients with AT deficiency [18, 19]. The pattern of thrombotic events in the family and the absence of other genetic causes further suggest that the thrombotic issues are due to this deficiency. Interestingly, all male patients in this family were affected, while female carriers did not experience thrombotic events. This sex bias may be due to X-chromosome inactivation and gene dosage effects, as females have a second functional X chromosome that could compensate for the loss of AT function. Similar observations have been reported in other haploinsufficiency disorders where females are asymptomatic due to the presence of a second functional allele [20, 21]. Future studies should explore the role of genetic modifiers and hormonal factors in thrombosis risk to better understand this sex bias in AT deficiency [16, 17]. A mild upward trend in APTT was observed during initial heparin therapy (Fig. 3), though a definitive correlation between this trend and the circulating levels/activity of wild-type versus mutant AT could not be established. This was due to the necessity of switching to urokinase thrombolysis following clinical deterioration and suspected heparin resistance. In such acute settings, therapeutic decisions must prioritize patient safety, which may preclude continuous monitoring for academic purposes. Given the clinical deterioration despite active anticoagulation therapy, the proband required venous sinus thrombectomy and thrombolysis to save his life. For patients who do not respond to standard anticoagulation therapy, venous sinus thrombectomy and thrombolysis should be considered as potential treatment options [1, 22]. Finally, environmental factors such as dehydration, exercise, and stress should be carefully managed in AT deficiency patients, as these factors can act as triggers for thrombotic events. In patients who stop anticoagulation therapy, the risk of recurrent thrombosis is 8.8% annually, highlighting the need for continuous monitoring and treatment [23]. Functional analysis of mutant AT and SDC4 AT is a key plasma glycoprotein that modulates the activity of procoagulant proteases in both intrinsic and extrinsic clotting pathways. Its main roles include inhibiting thrombin and factor Xa, which are critical for fibrin clot formation [24]. Two structural elements of AT, the reactive center loop and the D-helix, interact with coagulation proteases and HSPGs on endothelial cells, enhancing AT’s anticoagulant function. SDC4, a membrane-bound HSPG receptor, mediates AT’s signaling and enhances its activity [10, 25–27]. Disruption of AT’s interaction with SDC4 could increase thrombosis risk. The Phe155del mutation in SERPINC1 affects a conserved region in helix D, disrupting AT’s structure and stability [15, 16, 28]. This alteration likely plays a critical role in AT function by impairing the packing of the helix bundle and destabilizing the protein. Consistent with this structural interpretation, our molecular docking results showed that the number of hydrogen-bonding sites between AT and SDC4 was reduced in the Phe155del variant, with a corresponding increase in binding energy. These findings suggest that the mutation not only compromises AT’s structural integrity but also weakens its functional interaction with SDC4, providing a mechanistic explanation for the increased thrombotic risk. In co-immunoprecipitation assays, we confirmed that the Phe155del mutation in SERPINC1 would weaken the protein binding of AT and SDC4. Notably, the immunofluorescence morphology of endothelial cells showed that in the SERPINC1 Phe155del group, the co-expression of SERPINC1 and SDC4 showed a cluster-like aggregation in the cytoplasm, which may be related to abnormal aggregation with downstream signaling proteins through phase separation, endocytosis, exosome biosynthesis, and other mechanisms [29, 30]. To accurately model ligand-receptor interactions on endothelial cells and assess how the p.Phe155del mutation affects the interaction between AT and SDC4, we use the HUVEC model. Importantly, HUVECs do not naturally produce AT, so our in vitro experiments relied on the overexpression of both AT and SDC4. Therefore, the observed intracellular co-localization and reduced interaction between the mutant AT and SDC4 may not fully reflect the physiological conditions in vivo, where mutant AT may be present in lower concentrations and with limited extracellular availability. An alternative approach to better replicate the physiological setting would be to incubate recombinant AT with HUVECs expressing SDC4 in a co-culture system [9]. This approach could provide more insight into how AT behaves in the presence of endothelial cells and SDC4, reflecting a more physiologically relevant environment. This method would allow for a more direct analysis of how the mutation affects AT’s functional activity in the vascular context, with the potential for investigating local signaling and stabilization mechanisms at the endothelial interface. Based on the above evidence, we speculate the Phe155del mutation in SERPINC1 may weaken the binding of AT and SDC4, thereby disturbing normal AT–FXa interaction and increasing thrombotic tendency, which can manifest as VTE, including but not limited to CVST (Fig. 5). Fig. 5Possible mechanism by which the SERPINC1 p.Phe155del variant contributes to antithrombin deficiency and increased risk of venous thrombosis, with cerebral venous sinus thrombosis representing one potential clinical manifestation Possible mechanism by which the SERPINC1 p.Phe155del variant contributes to antithrombin deficiency and increased risk of venous thrombosis, with cerebral venous sinus thrombosis representing one potential clinical manifestation In summary, we report a rare familial case of CVST caused by the SERPINC1 p.Phe155del variant leading to Type I AT deficiency. The clinical phenotype can be primarily attributed to the quantitative deficiency of AT. Our molecular docking and cell-based assays further suggest that this variant may weaken the interaction between AT and SDC4, which could represent an additional mechanistic pathway predisposing to thrombosis. However, we acknowledge that this AT–SDC4 interaction remains speculative in the absence of in vivo validation. These findings provide new insights that warrant further mechanistic investigation, while also underscoring the importance of genetic screening and individualized anticoagulation strategies in patients with hereditary AT deficiency. Study limitations This study has notable limitations. We did not perform antigen measurements, secretion assays, or allele-specific quantification—key assays needed to clarify whether the p.Phe155del variant affects AT secretion, stability, or plasma availability. While in vitro experiments showed reduced AT–SDC4 binding, the patient’s thrombotic phenotype is more likely driven by quantitative AT deficiency, and the significance of impaired AT–SDC4 interaction remains speculative. Notably, molecular docking was based on a heparin-bound AT template, and we did not test whether binding depends on exogenous heparin, making these results hypothesis-generating. Future studies, including secretion and stability assays as well as transgenic mouse models, are required to confirm the in vivo significance of our findings. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1